[CAS NO. 1429651-50-2] HPOB
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1429651-50-2]
Store
Catalog
SLK-S7278
Brand
Selleck
CAS
1429651-50-2
DESCRIPTION [1429651-50-2]
Overview
| MDL | MFCD27952937 |
|---|---|
| Molecular Weight | 314.34 |
| Molecular Formula | C17H18N2O4 |
| SMILES | O=C(NO)C1=CC=C(CC(N(CCO)C2=CC=CC=C2)=O)C=C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1813 mL | 15.9063 mL | 31.8127 mL |
| 5 mM | 0.6363 mL | 3.1813 mL | 6.3625 mL |
| 10 mM | 0.3181 mL | 1.5906 mL | 3.1813 mL |
| 50 mM | 0.0636 mL | 0.3181 mL | 0.6363 mL |
Description
HPOB is a potent, selective inhibitor with of 56 nM, >30-fold selectivity over other HDACs.
Targets
In vitro
In normal (HFS) and transformed (LNCaP, A549, and U87) cells, HPOB induces acetylation of α-tubulin, however, not histones, and inhibits cell growth, however, not viability. In HFS cells, HPOB enhances transformed cell death induced by etoposide, doxorubicin, or SAHA. HPOB also enhancing etoposide-induced transformed cell death via the apoptotic pathway in transformed cells.
In vivo
In mice bearing CWR22 human prostate cancer xenografts, HPOB (300 mg/kg/d i.p.), when in combination with SAHA, causes suppression of the growth of established tumors, while produces no significant suppression when used alone.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.